ALL GMALL 07/2003(No longer recruiting): Therapy optimization by MRD-evaluation
relapsed/refractory
MEK 111759(No longer recruiting): Phase I/II Study on the MEK Inhibitor GSK1120212 in rel./ref. Leukemias
Ph/BCR ABL +
CABL001X2101(Active): Phase I Study of oral ABL001 in patients with CML or Ph+ALL
de novo/non-treated
EWALL-PH-02(No longer recruiting): Study of induction and consolidation therapy with Nilotinib in combination with chemotherapy in older patients with Ph/BCR-ABL+ ALL
Mature B-ALL/NHL
de novo/non-treated
ALL GMALL B-ALL/NHL 2002(No longer recruiting): Multicenter Study to Optimise Therapy of B-ALL, Burkitt NHL and High-Grade Non-Hodgkin Lymphoma in Adults
ASPIRE(No longer recruiting): Eltrombopag in Thrombocytopenic Subjects With MDS or AML
de novo/non-treated - Therapy concepts for specific genotypes - >= 60 years
AMLSG 10-07(No longer recruiting): SU11248 Combined With Standard Chemotherapy in Patients With FLT3 Mutated AML
de novo/non-treated - Therapy concepts for specific genotypes - All age groups
AMLSG 09-09(No longer recruiting): Phase III study of chemotherapy in combination with ATRA with or without gemtuzumab ozogamicin in patients with acute myeloid leukemia and NPM1 gene mutation
AMLSG 16-10(No longer recruiting): Protocol in Acute Myeloid Leukemia With FLT3-ITD
AMLSG 21-13(Active): Dasatinib in patients with newly diagnosed Core-Binding Factor AML
de novo/non-treated - Therapy concepts for all genotypes - All age groups
CLBH589H2101(No longer recruiting): Phase Ib study of Panobinostat and 5-Azacitidine for MDS, CMML or AML
de novo/non-treated - Therapy concepts for all genotypes - >= 60 years
SPARK-AML1(No longer recruiting): Randomized Study of AZD1152 Alone and in Combination With LDAC in Comparison With LDAC Alone in de novo AML
relapsed/refractory
CLBH589B2116(No longer recruiting): Dose-finding study of panobinostat plus Ara-C and mitoxantrone as salvage therapy for refractory or relapsed AML
CP4055-205(No longer recruiting): Elacytarabine (CP-4055) Plus Idarubicin as second-line treatment in AML
MEK 111759(No longer recruiting): Phase I/II Study on the MEK Inhibitor GSK1120212 in rel./ref. Leukemias
DASFREE(No longer recruiting): Evaluating Dasatinib therapy discontinuation in patients with CP-CML with stable CMR
de novo/non-treated
BFORE (AV001)(No longer recruiting): Phase 3 study of Bosutinib versus Imatinib in adult patients with de novo CP-CML
CML AMN107 2303(No longer recruiting): Imatinib vs. Nilotinib in newly diagnosed (Ph+) chronic myeloid leukemia in chronic phase (CML-CP)
ENEST1st(No longer recruiting): Nilotinib in adult patients with newly diagnosed Ph/BCR-ABL positive CML in chronic phase
CML IV(No longer recruiting): Imatinib vs. Imatinib+Interferon or Imatinib 800mg and SCT in CML
Intolerant/resistant to one TKI
AMN2128(No longer recruiting): Study of Nilotinib and Midazolam in CML Resistant and/or Intolerant Against One TKI
B1871039 (BYOND)(No longer recruiting): A Phase 4 Safety and Efficacy Study of Bosutinib in patients with CML
MDS: Myelodysplastic Syndrome
Intermedia II and high risk
ASPIRE(No longer recruiting): Eltrombopag in Thrombocytopenic Subjects With MDS or AML
ONO 1910(No longer recruiting): Randomized Study of ON 01910.Na in Refractory MDS With Excess Blasts
QOL II(No longer recruiting): Quality of Life and Symptoms in Patients With Newly Diagnosed MDS
Low risk and intermedia I
AZA-MDS-003(Active): Azacitidine Plus BSC vs Placebo Plus BSC in Red Blood Cell Transfusion-dependent Anemia and Thrombocytopenia Due to Lower-risk MDS
EUMDS(Active): European Registry for Low and Intermediate-1 MDS
MDS-005(No longer recruiting): A Study of Lenalidomide Versus Placebo in Subjects With Transfusion Dependent Anemia in Low Risk Myelodysplastic Syndrome (MDS) Without Del 5Q (MDS-005)
ARD12042(Active): Study With SAR302503 in Patients With Polycythemia Vera or Essential Thrombocythemia
Gilead-US-354-0101(Active): Safety and Efficacy of Momelotinib in Subjects With Polycythemia Vera or Essential Thrombocythemia
PEGASYS(No longer recruiting): Pegylated Interferon Alfa-2a Versus Hydroxyurea in PV and ET
Myelofibrosis
CINC424A2104 (HARMONY)(No longer recruiting): Phase I trial on Ruxolitinib in combination with BKM120 in patients with PMF, PPV-MF and PET-MF
CLBH589X2106(No longer recruiting): Panobinostat and Ruxolitinib in PMF, PPV-MF or PET-MF
CLDE225X2116(Active): Safety and Efficacy of LDE225 + INC424 in Patients With MF
EXPAND(Active): Dosefinding of Ruxolitinib with PMF, PPV-MF or PET-MF patients
Gilead GS-US-352-0101(Active): Phase 3 Study evaluating Momelotinib vs. Ruxolitinib in subjects with in PMF, Post-PV-MF, Post-ET-MF
Gilead GS-US-352-1214(Active): Phase III Study with Momelotinib versus BAT in patients with PMF, Post-PV, Post-ET after treatment with Ruxolitinib
JAKARTA(Active): Phase III Study of SAR302503 in Intermediate-2 and High Risk Patients With Myelofibrosis
JAKARTA2(Active): SAR302503 In MF Previously Treated With Ruxolitinib
JUMP (CINC424A2401)(No longer recruiting): Expanded access study of INC 424 for PMF, PPV MF or PET-MF
Polycythaemia vera
ARD12042(Active): Study With SAR302503 in Patients With Polycythemia Vera or Essential Thrombocythemia
Gilead-US-354-0101(Active): Safety and Efficacy of Momelotinib in Subjects With Polycythemia Vera or Essential Thrombocythemia
PEGASYS(No longer recruiting): Pegylated Interferon Alfa-2a Versus Hydroxyurea in PV and ET
RESPONSE(No longer recruiting): Study of INC424 in PV with Resistance to or Intolerance of Hydroxyurea
RESPONSE 2 (CINC424B2401)(Active): Phase IIIb Study Evaluating the Efficacy and Safety of Ruxolitinib Versus BAT in patients with Polycythemia Vera Resistant or Intolerant to Hydroxyurea
SCT: Stem cell transplantation
AML
RICMAC(No longer recruiting): Dose-Reduced Versus Standard Conditioning Prior Allo SCT for MDS/sAML
MDS
RICMAC(No longer recruiting): Dose-Reduced Versus Standard Conditioning Prior Allo SCT for MDS/sAML
Miscellaneous: Miscellaneous
Supportive Care
not specified / all stages
BUM-5/GVH(No longer recruiting): Efficacy and Safety Study of Budesonide to Treat Oral Chronic GvHD
